Zobrazeno 1 - 10
of 37
pro vyhledávání: ''
Autor:
Anne Chew, David M. Barrett, Yolanda D. Mahnke, Bruce L. Levine, Noelle Frey, David L. Porter, Pamela A. Shaw, J. Joseph Melenhorst, Carl H. June, Zhaohui Zheng, Susan R. Rheingold, Nancy Bunin, Shannon L. Maude, Vanessa E. Gonzalez, David T. Teachey, Stephan A. Grupp, Simon F. Lacey, Angela Shen, Richard Aplenc
Publikováno v:
New England Journal of Medicine. 371:1507-1517
Relapsed acute lymphoblastic leukemia (ALL) is difficult to treat despite the availability of aggressive therapies. Chimeric antigen receptor-modified T cells targeting CD19 may overcome many limitations of conventional therapies and induce remission
Autor:
Sandborn, William J., Su, Chinyu, Sands, Bruce E., D'Haens, Geert R., Vermeire, Séverine, Schreiber, Stefan, Danese, Silvio, Feagan, Brian G., Reinisch, Walter, Niezychowski, Wojciech, Friedman, Gary, Lawendy, Nervin, Yu, Dahong, Woodworth, Deborah, Mukherjee, Arnab, Zhang, Haiying, Healey, Paul, Panés Díaz, Julià, OCTAVE Induction 1, OCTAVE Induction 2, OCTAVE Sustain Investigators., Guardiola, Jordi
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
New England journal of medicine, 376(18), 1723-1736. Massachussetts Medical Society
Universidad de Barcelona
New England journal of medicine, 376(18), 1723-1736. Massachussetts Medical Society
Background: Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial. We further evaluated the efficacy of tofacitinib as induction and maintenanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f2d0d357d18521a403fbcc3cdf5d19d
http://hdl.handle.net/2445/189961
http://hdl.handle.net/2445/189961
Autor:
Xavier Forns, B. Bernstein, Eric M. Yoshida, Thomas Berg, Stefan Zeuzem, Mitchell L. Shiffman, Roger Trinh, Barbara Da Silva-Tillmann, Heiner Wedemeyer, Christophe Hézode, Thomas Podsadecki, Christine Collins, Kosh Agarwal, Campbell Andrew L, Sandra S. Lovell, Kris V. Kowdley, Fred Poordad
Publikováno v:
Recercat. Dipósit de la Recerca de Catalunya
instname
Dipòsit Digital de la UB
Universidad de Barcelona
instname
Dipòsit Digital de la UB
Universidad de Barcelona
Background Interferon-containing regimens for the treatment of hepatitis C virus (HCV) infection are associated with increased toxic effects in patients who also have cirrhosis. We evaluated the interferon-free combination of the protease inhibitor A
Autor:
Nezam, Afdhal, K Rajender, Reddy, David R, Nelson, Eric, Lawitz, Stuart C, Gordon, Eugene, Schiff, Ronald, Nahass, Reem, Ghalib, Norman, Gitlin, Robert, Herring, Jacob, Lalezari, Ziad H, Younes, Paul J, Pockros, Adrian M, Di Bisceglie, Sanjeev, Arora, G Mani, Subramanian, Yanni, Zhu, Hadas, Dvory-Sobol, Jenny C, Yang, Phillip S, Pang, William T, Symonds, John G, McHutchison, Andrew J, Muir, Mark, Sulkowski, Paul, Kwo, Ziad, Younes
Publikováno v:
New England Journal of Medicine. 370:1483-1493
Effective treatment for hepatitis C virus (HCV) genotype 1 infection in patients who have not had a sustained virologic response to prior interferon-based therapy represents an unmet medical need.We conducted a phase 3, randomized, open-label study i
Autor:
Tami Pilot-Matias, David R. Nelson, Mark S. Sulkowski, Wangang Xie, Paul Y. Kwo, George Liossis, Fred Poordad, Gregory T. Everson, Amit Khatri, Lois Larsen, Stefan Zeuzem, Graham R. Foster, Kris V. Kowdley, B. Bernstein, Eric Lawitz, Daniel E. Cohen, Thomas Podsadecki
Publikováno v:
New England Journal of Medicine. 370:222-232
An interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the nonnucleoside polymerase inhibitor ABT-333, and ribavirin showed efficacy against the hepatitis C virus (HCV) in a pilot study involving patients with HC
Autor:
Stuart C. Gordon, David L. Wyles, Aasim Sheikh, Maribel Rodriguez-Torres, John McNally, Sarah Arterburn, Robert H. Hyland, M. Davis, Eric Lawitz, Tarek Hassanein, G. Mani Subramanian, Kris V. Kowdley, Zeid Kayali, Ira M. Jacobson, William T. Symonds, Diana M. Brainard, Deyuan Jiang, Michael Schultz, Alessandra Mangia, K. Rajender Reddy, L. Nyberg, Edward Gane, John G. McHutchison, Zobair M. Younossi
Publikováno v:
New England Journal of Medicine. 368:1878-1887
In phase 2 trials, the nucleotide polymerase inhibitor sofosbuvir was effective in previously untreated patients with chronic hepatitis C virus (HCV) genotype 1, 2, or 3 infection.We conducted two phase 3 studies in previously untreated patients with
Autor:
Catherine A.M. Stedman, M.M. Berrey, Evguenia S. Svarovskaia, William T. Symonds, Xiao Ding, Edward Gane, R. Hindes, Robert H. Hyland
Publikováno v:
New England Journal of Medicine. 368:34-44
The standard treatment for hepatitis C virus (HCV) infection is interferon, which is administered subcutaneously and can have troublesome side effects. We evaluated sofosbuvir, an oral nucleotide inhibitor of HCV polymerase, in interferon-sparing and
Autor:
José Baselga, Ellie Guardino, Sunil Verma, Ian E. Krop, Steven R. Olsen, Liang Fang, K. L. Blackwell, Véronique Diéras, Manfred Welslau, M. Lu, Mark D. Pegram, David Miles, Luca Gianni, Do Youn Oh
Publikováno v:
New England Journal of Medicine. 367:1783-1791
Background Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate incorporating the human epidermal growth factor receptor 2 (HER2)–targeted antitumor properties of tras tuz u mab with the cytotoxic activity of the microtubule-inhibitory age
Autor:
Peng Sun, Kevin B. Kim, Howard A. Burris, Omid Hamid, Jeffrey A. Sosman, Jonathan Cebon, Alicia Allred, Peter F. Lebowitz, Gerald S. Falchook, Richard F. Kefford, Karl D. Lewis, Daniele Ouellet, Keith T. Flaherty, J. R. Infante, Lynn M. Schuchter, Adil Daud, Rene Gonzalez, Georgina V. Long, Jeffrey S. Weber, Nageatte Ibrahim, Igor Puzanov, Ragini Kudchadkar, Ajay Singh, Alain Algazi, Shonda M Little, Kiran Patel
Publikováno v:
The New England journal of medicine, vol 367, iss 18
BackgroundResistance to therapy with BRAF kinase inhibitors is associated with reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a s
Autor:
Woodrow Wells, Robert Pearcey, Marina S. Djurfeldt, Lois E. Shepherd, Chaim Shustik, Mary Gospodarowicz, Douglas A. Stewart, Bingshu E. Chen, Sandra J. Horning, Joseph M. Connors, Michael Crump, Jane N. Winter, Ralph M. Meyer, A. Rashid Dar
Publikováno v:
New England Journal of Medicine. 366:399-408
Chemotherapy plus radiation treatment is effective in controlling stage IA or IIA nonbulky Hodgkin's lymphoma in 90% of patients but is associated with late treatment-related deaths. Chemotherapy alone may improve survival because it is associated wi